Yersinia enterocolitica Infectious Disease (Yersiniosis): A Comprehensive Disease Characterization

Disease: Yersinia enterocolitica infectious disease (yersiniosis) MONDO ID: MONDO:0042370 · ICD-10: A04.6 · ICD-11: 1A03 · MeSH: D015008 (Yersinia enterocolitica infection) / D015009 (Yersiniosis) · Pathogen NCBI Taxon: NCBI:txid630 · Category: Infectious Disease

Summary

Yersinia enterocolitica infectious disease (yersiniosis) is a foodborne zoonotic enteric infection caused by the Gram-negative coccobacillus Yersinia enterocolitica. It is most commonly acquired through consumption of undercooked or contaminated pork, with swine serving as the principal reservoir of the human-pathogenic bioserotype 4/O:3 (PMID: 26403101, PMID: 29307129). The organism is psychrotolerant (grows at 4 °C) and forms biofilms throughout the cold food chain, making it a persistent hazard in refrigerated foods, dairy, and blood products (PMID: 41539755). Non-pestis yersiniosis has shown the largest increase in reported incidence of any bacterial enteric infection in the United States during 2016–2023 (PMID: 42720049).

Mechanistically, after ingestion the bacterium colonizes the terminal ileum, uses the outer-membrane adhesin invasin to bind host β1 integrins on M cells overlying Peyer's patches, and invades follicle-associated lymphoid tissue (PMID: 27107739). At 37 °C the ~70-kb pYV virulence plasmid activates (via the VirF/LcrF regulator) a type III secretion system (T3SS) that injects Yop effector proteins into phagocytes, subverting phagocytosis, actin dynamics, and NF-κB/MAPK survival and inflammasome signaling — YopP/YopJ in particular drives macrophage/dendritic-cell death (PMID: 22563435). Host iron status is a decisive branch point: because Y. enterocolitica lacks its own high-affinity siderophore, iron overload and deferoxamine therapy dramatically increase virulence and the risk of septicemia, lowering the murine LD₅₀ by more than 5 log units (PMID: 12019084).

The clinical spectrum is age- and host-dependent: self-limiting enterocolitis in young children; pseudoappendicitis (terminal ileitis / mesenteric adenitis) in older children and young adults; and invasive septicemia with hepatic/splenic abscesses in iron-overloaded or immunocompromised hosts (PMID: 15254824, PMID: 9376035). Important post-infectious sequelae include HLA-B27-associated reactive arthritis, erythema nodosum, uveitis (PMID: 40473988, PMID: 7221767), and autoimmune thyroid disease / Graves' disease via molecular mimicry between the bacterial outer-membrane porin OmpF and the TSH receptor (PMID: 32564766, PMID: 20484489). Most cases resolve without antibiotics; invasive disease is treated with third-generation cephalosporins, fluoroquinolones, and/or aminoglycosides — the organism is intrinsically resistant to ampicillin and first-generation cephalosporins (PMID: 10803262). No human vaccine exists; prevention relies on farm-to-fork food-chain hygiene (PMID: 19058737).

1. Disease Information

Overview. Yersiniosis is an enteric infection caused by Yersinia enterocolitica, a Gram-negative, facultatively anaerobic, non-lactose-fermenting member of the Enterobacteriaceae. It is one of the more common causes of bacterial gastroenteritis in temperate regions and is notable for its psychrotolerance and its zoonotic, pork-associated transmission. Clinically it manifests along a spectrum from acute enteritis/enterocolitis to pseudoappendicitis and, in vulnerable hosts, septicemia (PMID: 15254824).

Key identifiers. MONDO:0042370; ICD-10 A04.6 (Enteritis due to Yersinia enterocolitica); ICD-11 1A03 (Enteritis due to Yersinia enterocolitica); MeSH D015008/D015009; causative organism NCBI:txid630.

Synonyms / alternative names. Yersiniosis; intestinal yersiniosis; Yersinia enterocolitica enteritis/enterocolitis; enteric yersiniosis; non-pestis yersiniosis.

Data provenance. This report aggregates disease-level evidence from primary literature, microbiological surveillance, case reports, meta-analysis, and experimental (rodent/in-vitro) studies rather than individual EHR records.

2. Etiology

Causal factor (infectious). The disease is caused by pathogenic bioserotypes of Y. enterocolitica. Globally, the principal human-pathogenic serotypes are O:3, O:9, O:8, and O:5,27, with bioserotype 4/O:3 dominant in most regions (PMID: 29307129, PMID: 40445798). Pigs are the primary reservoir; insufficiently cooked pork is the main vehicle (PMID: 26403101).

Environmental / exposure risk factors. Consumption of raw or undercooked pork (including chitterlings), unpasteurized dairy, and contaminated water; cold-chain storage that permits psychrotolerant growth; transfusion via contaminated blood products; occupational contact in the pork production chain. Young age is a risk factor for enterocolitis.

Host risk factors (the key modifier — iron). Iron overload and iron-chelation therapy with deferoxamine are the most important host risk factors for severe/invasive disease. In a mouse model, deferoxamine pretreatment decreased the LD₅₀ of Y. enterocolitica by >5 log units, whereas deferiprone did not (PMID: 12019084). Transfusion-dependent conditions (β-thalassemia, sickle cell disease) and dialysis iron supplementation predispose to fulminant infection (PMID: 31219970, PMID: 21266629, PMID: 11698009, PMID: 21151549). Diabetes, malignancy, and other immunocompromising conditions also predispose to bacteremia (PMID: 9376035).

Genetic host factor. HLA-B27 is a genetic susceptibility factor for the post-infectious complication of reactive arthritis (PMID: 7221767).

Protective factors. Thorough cooking of pork, pasteurization, cold-chain hygiene, and biosecurity reduce exposure. Mucosal innate defenses (e.g., Paneth-cell α-defensin HD6, which entraps enteric pathogens in self-assembled nanonets) limit invasion (PMID: 22722251). Use of the oral iron chelators deferiprone/deferasirox instead of deferoxamine avoids promoting bacterial growth (PMID: 12019084, PMID: 19413741).

Gene–environment interaction. The clearest interaction is iron availability × siderophore biology: exogenous ferrioxamine (from deferoxamine) supplies iron the bacterium cannot otherwise scavenge, converting a contained mucosal infection into systemic disease. A second interaction is HLA-B27 × enteric infection, where a genetically predisposed host mounts an aberrant post-infectious arthritic response.

3. Phenotypes

Phenotype Type Onset / course Frequency HPO suggestion
Diarrhea (often watery, sometimes bloody) Symptom Acute, self-limiting Very common in enterocolitis HP:0002014
Abdominal pain (right-lower-quadrant) Symptom Acute Common; prominent in pseudoappendicitis HP:0002027 / HP:0002574
Fever Sign Acute Common HP:0001945
Terminal ileitis / mesenteric lymphadenitis Clinical sign Subacute Older children/adults HP:0002583 (enterocolitis)
Pseudoappendicitis Clinical syndrome Acute Older children/young adults HP:0002605 (approximate)
Septicemia / bacteremia Lab/clinical Acute, severe Rare; iron-overloaded/immunocompromised HP:0100806
Hepatic/splenic abscesses Manifestation Invasive disease Rare HP:0012199 / HP:0020104
Reactive arthritis (asymmetric, lower-limb) Post-infectious Days–weeks after infection ~1/1000 (ReA overall); young adults 18–40 HP:0001369
Erythema nodosum Post-infectious skin sign Weeks after Occasional HP:0012219
Uveitis Post-infectious Weeks after Occasional HP:0000554
Graves' disease / autoimmune thyroiditis Post-infectious autoimmune Delayed Association (see §5) HP:0100647

Characteristics. Onset is typically acute; enterocolitis is generally self-limiting (1–3 weeks). Severity ranges from mild (children) to life-threatening (septicemia in iron overload). Post-infectious immunological syndromes are episodic/delayed (PMID: 8363822, PMID: 3545747).

Quality-of-life impact. Acute enterocolitis causes short-term disability from diarrhea/pain; pseudoappendicitis may lead to unnecessary appendectomy. Reactive arthritis and other post-infectious syndromes can cause prolonged joint pain and functional impairment persisting weeks to months (PMID: 32648451).

4. Genetic / Molecular Information

Yersiniosis is an infectious, not a Mendelian, disease; there are no causal human genes. The relevant genetics are (a) host susceptibility loci and (b) bacterial virulence genes.

Host genetics. HLA-B27 predisposes to post-infectious reactive arthritis (PMID: 7221767). No causal germline variants, chromosomal abnormalities, or pathogenic ACMG-classified variants apply to the disease itself. gnomAD/ClinVar entries are not applicable.

Bacterial virulence genetics. Pathogenicity of biotypes 1B and 2–5 depends on both chromosomal and pYV plasmid-borne genes; biotype 1A lacks pYV (PMID: 28400007).

5. Environmental Information

Infectious agent. Yersinia enterocolitica (NCBI:txid630); a species divided into ~6 biotypes and ~60 O-serotypes, with O:3, O:9, O:8, O:5,27 principally associated with human disease (PMID: 40445798).

Environmental factors. The organism's psychrotolerance (growth at 4 °C) and biofilm formation enable persistence across refrigerated foods and food-processing environments; slaughterhouses (40.2%) and farmers' markets (34.8%) are high-risk contamination zones (PMID: 41539755). Contaminated red-blood-cell units support proliferation during cold storage, a recognized transfusion hazard (PMID: 33341965).

Lifestyle / dietary factors. Consumption of raw/undercooked pork (notably chitterlings), unpasteurized milk/dairy (18% of US outbreak vehicles), and untreated water (PMID: 42720049). Pork accounted for 46% of identified US outbreak vehicles.

Reservoirs. Swine are the primary reservoir (bioserotype 4/O:3); wildlife (badgers, roe deer, mustelids), poultry, and other livestock also carry the organism (PMID: 40582279, PMID: 41527869).

6. Mechanism / Pathophysiology

Ordered causal chain (initiating exposure → clinical manifestation)

  1. Ingestion of Y. enterocolitica in contaminated pork/dairy/water leads to delivery of viable bacteria to the small intestine (survival aided by psychrotolerance and acid tolerance).
  2. Bacteria colonize the terminal ileum; expression of chromosomal adhesins/invasins is favored at intestinal temperature/pH.
  3. Invasin binds host β1 integrins on the apical surface of M cells overlying Peyer's patches, resulting in receptor-mediated internalization and translocation across the follicle-associated epithelium (PMID: 27107739, PMID: 26731748). (Invasin is rapidly degraded by gut proteases, which limits the efficiency of this step — PMID: 21501502.)
  4. Uptake by lamina propria CD103⁺ dendritic cells and monocyte-derived phagocytes (invasin-dependent; YadA dispensable) leads to dissemination to mesenteric lymph nodes, and in some hosts the spleen and liver (PMID: 27107739).
  5. At 37 °C, the VirF/LcrF regulator induces the pYV-encoded T3SS, which upon host-cell contact injects Yop effectors (YopH, YopE, YopT, YopO, YopP/J, YopM) into phagocytes (PMID: 8709853).
  6. Yop effectors subvert innate immunity: YopH/E/T/O disrupt phagocytosis and actin dynamics; YopP/YopJ inhibits NF-κB/MAPK survival pathways, causing macrophage/DC apoptosis and modulating caspase-1/IL-1β (PMID: 22563435, PMID: 18559430). This results in immune evasion and local tissue inflammation → enterocolitis / terminal ileitis / mesenteric adenitis / pseudoappendicitis.
  7. YstA heat-stable enterotoxin activates guanylate cyclase in enterocytes, contributing to secretory diarrhea (PMID: 28400007, PMID: 30961808).

Branch A — host iron status → septicemia. Because Y. enterocolitica lacks a high-affinity siderophore, iron overload or deferoxamine therapy supplies chelated iron (ferrioxamine), which leads to unrestrained bacterial replication and systemic septicemia with hepatic/splenic abscesses (PMID: 12019084, PMID: 31219970).

Branch B — post-infectious autoimmunity. In HLA-B27⁺ hosts, enteric infection triggers reactive arthritis (PMID: 7221767). Independently, molecular mimicry between the bacterial outer-membrane porin OmpF (aa190–197) and a leucine-rich domain of the TSH receptor generates cross-reactive, thyroid-stimulating antibodies, contributing to Graves' disease / autoimmune thyroid disease (PMID: 20484489, PMID: 32564766).

Mechanistic categories

7. Anatomical Structures Affected

8. Temporal Development

9. Inheritance and Population (Epidemiology)

10. Diagnostics

Culture (gold standard). Stool culture on CIN (cefsulodin–irgasan–novobiocin) agar with cold enrichment (4 °C) enhances recovery — cold enrichment recovered ~25% of 4/O:3 and 2/O:9 strains not otherwise detected (PMID: 19219471). Blood culture in suspected septicemia.

Bio/serotyping. Congo-red magnesium-oxalate (CR-MOX) agar detects the pYV virulence plasmid; biochemical panels assign biotype; agglutination/PCR serotyping identifies O:3, O:9, O:8, O:5,27 (PMID: 19219471, PMID: 40445798).

Molecular confirmation. PCR for virulence genes (ail, ystA/ystB, virF, yadA, inv, myfA) distinguishes pathogenic from non-pathogenic (biotype 1A) strains; 16S rRNA and gyrB sequencing resolves Y. enterocolitica-like species; multiplex/quadruplex RT-qPCR patho-serotyping is available (PMID: 19219471, PMID: 40445798).

Serology. Anti-Yersinia antibody titers (e.g., against O:3, O:9) support diagnosis of post-infectious syndromes such as reactive arthritis (PMID: 9376035). Caveat: O:9 cross-reacts serologically with Brucella.

Imaging. CT/ultrasound in pseudoappendicitis shows terminal ileitis and mesenteric lymphadenopathy (helping avoid unnecessary appendectomy).

Differential diagnosis. Acute appendicitis, Crohn's disease/terminal ileitis, Campylobacter/Salmonella/Shigella enterocolitis, mesenteric adenitis of other cause.

11. Outcome / Prognosis

12. Treatment

General principle. Uncomplicated enterocolitis is self-limiting and generally does not require antibiotics; supportive care (rehydration) suffices. Antibiotics are indicated for invasive/septicemic disease and in high-risk hosts.

Antimicrobial susceptibility profile.

Antimicrobial class Susceptibility Evidence
Ampicillin, 1st-gen cephalosporins (cefazolin) Intrinsically RESISTANT (chromosomal β-lactamases blaA/blaB) PMID: 10803262, PMID: 10755244
3rd-gen cephalosporins (cefotaxime, ceftriaxone) Susceptible — drug of choice PMID: 10803262, PMID: 21266629
Fluoroquinolones (ciprofloxacin, ofloxacin) Susceptible; highly effective in models PMID: 10803262, PMID: 1952849
Aminoglycosides (gentamicin) Susceptible PMID: 10755244, PMID: 20828475
TMP-SMX, tetracyclines, chloramphenicol, imipenem, aztreonam Susceptible PMID: 10755244

Susceptibility is independent of the pYV plasmid (PMID: 10755244). In murine systemic infection, newer β-lactams may fail while fluoroquinolones (ofloxacin, 5 mg/kg) are very effective (PMID: 1952849).

Regimens. Septicemia is typically treated with a third-generation cephalosporin (e.g., ceftriaxone) ± an aminoglycoside or a fluoroquinolone; combination therapy is used for severe disease. NCIT term suggestions: Ceftriaxone (NCIT:C749), Ciprofloxacin (NCIT:C405), Gentamicin (NCIT:C557), Trimethoprim-Sulfamethoxazole (NCIT:C273).

Critical host management. In iron-overloaded patients, discontinue deferoxamine during infection and consider deferiprone/deferasirox, which do not promote bacterial growth (PMID: 12019084, PMID: 19413741).

AMR surveillance. Prudent antimicrobial use in pig farming is emphasized to limit resistance-gene spread via horizontal transfer (PMID: 41413462, PMID: 35369517).

Advanced/experimental therapeutics. Not applicable — no gene/cell/RNA/targeted therapies; treatment is antimicrobial and supportive.

13. Prevention

14. Other Species / Natural Disease

15. Model Organisms

Mechanistic Model / Integrated Interpretation

   Contaminated pork/dairy/water (psychrotolerant, biofilm)
                     │  ingestion
                     ▼
        Terminal ileum colonization
                     │  invasin → β1 integrin (M cells)
                     ▼
        Peyer's patch invasion ── (gut proteases degrade invasin: limiting)
                     │  CD103+ DC / monocyte uptake
                     ▼
        Mesenteric lymph nodes ──► spleen/liver (dissemination)
                     │  37°C → VirF/LcrF → T3SS
                     ▼
        Yop injection (YopH/E/T/O/P-J/M)
          inhibits phagocytosis, NF-κB/MAPK, inflammasome
                     │
        ┌────────────┼───────────────────────────┐
        ▼            ▼                            ▼
  Enterocolitis /   Branch A: IRON OVERLOAD    Branch B: POST-INFECTION
  pseudoappendicitis  + deferoxamine            HLA-B27 → reactive arthritis
  (+ YstA enterotoxin) → SEPTICEMIA,            OmpF≈TSHR mimicry → Graves'
   → diarrhea        hepatic/splenic abscess    erythema nodosum, uveitis

Upstream vs downstream. Invasin-mediated M-cell entry is the upstream initiating event; T3SS/Yop immune subversion is the central amplifying node; enterocolitis, septicemia, and autoimmune sequelae are downstream outcomes gated by host iron status and HLA background.

Evidence Base (key literature)

PMID Contribution Type
26403101 Swine/pork as reservoir & main infection source Review
29307129 9.31% pig-tonsil prevalence; 4/O:3 = 95.74% Surveillance
12019084 Deferoxamine lowers LD₅₀ >5 log; deferiprone does not Model organism
31219970 Transfusional iron overload → fulminant yersiniosis Case report
27107739 Invasin-dependent DC/M-cell uptake & dissemination Mechanistic
22563435 YopJ inhibits survival pathways → macrophage death Mechanistic
40473988 Y. enterocolitica as post-enteric ReA trigger Review
7221767 ReA linked to HLA-B27 Case report
32564766 Graves' association OR 6.12 (3.71–10.10) Meta-analysis
20484489 OmpF–TSHR molecular mimicry In vitro
42720049 Rising US incidence; pork 46%, dairy 18% Surveillance
19219471 Culture/cold-enrichment diagnostics; bioserotype prevalence Surveillance
10803262 3rd-gen cephalosporins & ciprofloxacin most active In vitro
1952849 Fluoroquinolone efficacy vs β-lactam failure Model organism
15254824 Three clinical syndromes defined Review
19058737 Slaughter hygiene as key prevention Surveillance
8363822 Rodent model fidelity to human disease Review
28400007 ystA best pathogenicity marker; ystB for 1A Molecular
28283072 ail as main chromosomal virulence marker Molecular
41539755 Psychrotolerance/biofilm across cold chain Surveillance

Limitations and Knowledge Gaps

Proposed Follow-up Actions

  1. Extract absolute incidence/prevalence from GBD, CDC FoodNet, and Orphanet to complete Section 9 quantitatively.
  2. Systematic review of HLA-B27 penetrance for Yersinia-triggered reactive arthritis (attributable risk, time-to-onset).
  3. Prospective study of oral iron-chelator choice (deferiprone/deferasirox vs deferoxamine) on yersiniosis incidence in transfusion-dependent patients.
  4. Genomic surveillance (One Health) linking swine and human isolates via SNP/MLST to quantify attributable transmission and AMR gene flow (PMID: 41413462).
  5. 4/O:3-based infection models to align mechanistic studies with the globally dominant human bioserotype.
  6. Mechanistic test of OmpF–TSHR mimicry in vivo to establish causality for the Graves' association.

Report compiled from 13 confirmed findings across 73 reviewed papers over 5 investigation iterations. Evidence types are labeled (human clinical, model organism, in vitro, computational, surveillance/review) throughout.